—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs)...
Monthly reductions in seizure frequency of 90.9% among participants treated for ≥48 months in the OLE, with 38% achieving ≥1...
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire...
First video-documented ALS reversal marks a new era for brain health achieved through noninvasive computerized brain-temperature modulation, confirmed by electrophysiological,...
Phase 2 clinical trial initiated to evaluate SEMA3A mAb as potential treatment for Alport syndromeMilestone payment to Evotec expected upon...
MIDDLETON, Wis., Dec. 3, 2025 /PRNewswire/ -- Natus Medical Incorporated announced the electrographic status epilepticus diagnosis capability of its BrainWatch point-of-care...
First-of-its-kind partnership between Aidoc and NVIDIA MONAI takes models from lab to scaled clinical use; new Quibim collaboration adds best-in-class Prostate...
VANCOUVER, BC / ACCESS Newswire / December 2, 2025 / StimCell Energetics Inc. (OTCQB:STME) ("StimCell" or the "Company"), a biotech...
The multi-year partnership launches with focus on epilepsy, rare disease and AISAN FRANCISCO and ATLANTA, Dec. 02, 2025 (GLOBE NEWSWIRE)...
Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease...
Transaction boosts Solta Medical's position to meet rising demand in China's growing aesthetics market LAVAL, QC / ACCESS Newswire /...
Nipocalimab is the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are...
New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in patients with Dravet...
The company will showcase a wave of transformative innovations designed to address the most pressing challenges in healthcare, spanning the...
SIGNA Bolt1, a new 3T MRI scanner, is designed with a next-gen gradient system engineered to support precision diagnostics, clinical...
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the...
One Oral Late Breaking Communication and Two Poster PresentationsNEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp....
NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG),...
LONDON, Nov. 26, 2025 /PRNewswire/ -- Queen Square Imaging Centre – the world-leading centre treating patients with Essential Tremor and...
Non-Ionizing Technology Makes Medical Imaging Completely Portable and Ultra-AffordableCHICAGO, Nov. 25, 2025 /PRNewswire/ -- RSNA Booth 8100 – OmniZare, an innovative medical...